Noble Financial Issues Negative Outlook for TNXP Earnings

Key Points

• Noble Financial has downgraded its Q3 2025 earnings estimate for Tonix Pharmaceuticals, projecting a larger loss of ($3.93) per share, compared to the earlier estimate of ($2.99).
• Tonix Pharmaceuticals recently reported earnings that missed analyst expectations, showing a loss of ($3.86) per share against a consensus estimate of ($3.10).
• The stock has seen significant volatility, with a 12-month price range between $6.76 and $130.00, and recently traded down by 3.2%.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Equities researchers at Noble Financial cut their Q3 2025 earnings estimates for shares of Tonix Pharmaceuticals in a research note issued to investors on Wednesday, August 13th. Noble Financial analyst R. Leboyer now anticipates that the company will post earnings per share of ($3.93) for the quarter, down from their prior estimate of ($2.99). The consensus estimate for Tonix Pharmaceuticals' current full-year earnings is ($1,762.50) per share. Noble Financial also issued estimates for Tonix Pharmaceuticals' Q4 2025 earnings at ($4.44) EPS, FY2025 earnings at ($14.95) EPS, Q1 2026 earnings at ($3.16) EPS, Q2 2026 earnings at ($2.73) EPS, Q3 2026 earnings at ($2.29) EPS, Q4 2026 earnings at ($1.56) EPS and FY2026 earnings at ($9.74) EPS.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The company reported ($3.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.10) by ($0.76). Tonix Pharmaceuticals had a negative return on equity of 57.93% and a negative net margin of 828.22%. The business had revenue of $2.00 million for the quarter, compared to analyst estimates of $2.60 million.

A number of other analysts have also recently commented on TNXP. Alliance Global Partners reiterated a "buy" rating on shares of Tonix Pharmaceuticals in a research note on Tuesday, June 3rd. Wall Street Zen upgraded shares of Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th.

Tonix Pharmaceuticals Price Performance

Tonix Pharmaceuticals stock traded down $11.28 during midday trading on Friday, reaching $40.07. The company's stock had a trading volume of 7,942,725 shares, compared to its average volume of 1,847,557. The stock has a market capitalization of $351.41 million, a P/E ratio of -1.02 and a beta of 1.70. The stock's 50-day simple moving average is $41.39 and its 200-day simple moving average is $27.16. Tonix Pharmaceuticals has a 52-week low of $6.76 and a 52-week high of $130.00.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TNXP. Geode Capital Management LLC boosted its stake in shares of Tonix Pharmaceuticals by 1,600.1% in the fourth quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company's stock worth $650,000 after buying an additional 1,855,907 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Tonix Pharmaceuticals in the fourth quarter worth about $526,000. Two Sigma Investments LP purchased a new stake in shares of Tonix Pharmaceuticals during the 4th quarter worth about $66,000. IFP Advisors Inc acquired a new stake in shares of Tonix Pharmaceuticals during the 1st quarter valued at about $179,000. Finally, Jane Street Group LLC raised its holdings in Tonix Pharmaceuticals by 5,932.3% in the 4th quarter. Jane Street Group LLC now owns 1,662,682 shares of the company's stock worth $548,000 after purchasing an additional 1,635,119 shares during the period. 82.26% of the stock is owned by institutional investors and hedge funds.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.